Elena Prokupets
Director/Board Member at OncoPep, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| William McKee | M | 62 |
NextRNA Therapeutics, Inc.
 NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 2 years |
| Kendra Adams | F | 47 | 4 years | |
| Bruce Downey | M | 76 |
OncoPep, Inc.
 OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | 13 years |
| Simon S. Jones | M | - |
Regenacy Pharmaceuticals LLC
 Regenacy Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA. | 8 years |
| Doris Peterkin | F | - |
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | 14 years |
| Bihua Chen | F | 55 | 9 years | |
| Kenneth Anderson | M | 72 |
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA.
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 14 years |
| Alain J. Cohen | M | 57 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 8 years |
| Malcolm Salter | M | 84 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 9 years |
| Julia Novina | F | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 years |
| Dominique Verhelle | M | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 years |
| Andrew Hirsch | M | 53 | 4 years | |
| C. William Bachman | M | - |
Rochester Christian University
| - |
| Rich Handler | M | 62 |
Rochester Christian University
| - |
| Jay L. Eastman | M | - |
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | - |
| Jolie Siegel | F | 48 | 4 years | |
| Glenn Dubin | M | 67 | 3 years | |
| Joslyn Dobson | F | - |
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | 14 years |
| Carl Novina | M | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 years |
| Robert B. Goergen | M | 84 |
Rochester Christian University
| 42 years |
| Richard Plympton | M | - |
Rochester Christian University
| - |
| M. Isabel Chiu | M | - | 8 years | |
| Sjoerd A. Stoffelsma | M | - |
Rochester Christian University
| - |
| Kathy Waller | F | 65 |
Rochester Christian University
| - |
| Joel Seligman | M | 74 |
Rochester Christian University
| 19 years |
| Lance Drummond | M | 69 |
Rochester Christian University
| - |
| Rohtash Mal | M | - |
Rochester Christian University
| - |
| Drew Dennison | M | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 years |
| Michael F. Ritz | M | - |
Rochester Christian University
| - |
| Albert Brault | M | - |
Rochester Christian University
| - |
| Stephen Dewhurst | M | - |
Rochester Christian University
| 34 years |
| Martin Gorovsky | M | - |
Rochester Christian University
| - |
| Mark Misuyrewucz | M | - |
Rochester Christian University
| - |
| Francis L. Price | M | - |
Rochester Christian University
| - |
| Da Guang Wang | M | - |
Regenacy Pharmaceuticals LLC
Regenacy Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA. | - |
| Scott Boyle | M | 46 | 2 years | |
| Cathy Folster | F | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 years |
| Christine Henderson | F | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | - |
| Susan Langer | F | 33 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 years |
| Mayra Reyes-Armour | M | - | 3 years | |
| Stewart Fisher | M | 57 | 8 years | |
| Jooeun Bae | M | - |
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | - |
| Shi Xiang Yan | M | - |
Regenacy Pharmaceuticals LLC
Regenacy Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA. | - |
| Kevin P. Thompson | M | - |
Rochester Christian University
| 15 years |
| Lori Friedman | M | 60 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 1 years |
| Michael Huang | M | 50 |
Regenacy Pharmaceuticals LLC
Regenacy Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA. | - |
| Adrian Bignami | M | - | 3 years | |
| Andrea Armstrong | F | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 years |
| Nikhil C. Munshi | M | - |
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | - |
| Nomi Bergman | F | 60 |
Rochester Christian University
| 13 years |
| James L. McGrath | M | - |
Rochester Christian University
| - |
| Judith L. Pipher | M | - |
Rochester Christian University
| - |
| Kelly Schick | F | 44 | 3 years | |
| Barry W. Florescue | M | 79 |
Rochester Christian University
| - |
| Regis J. O'Keefe | M | - |
Rochester Christian University
| - |
| Joel Seth Beckman | M | 68 |
Rochester Christian University
| - |
| Ursula Burns | F | 65 |
Rochester Christian University
| - |
| Robert Keegan | M | 76 |
Rochester Christian University
| - |
| Michael D. DePaolis | M | 67 |
Rochester Christian University
| - |
| Frank G. Creamer | M | 77 |
Rochester Christian University
| - |
| Carol Davidson | M | 68 |
Rochester Christian University
| - |
| Barry A. Polisky | M | 78 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | - |
| Sandra A. Parker | F | 74 |
Rochester Christian University
| - |
| Hugo Sonnenschein | M | 83 |
Rochester Christian University
| - |
| Arunas A. Chesonis | M | 61 |
Rochester Christian University
| - |
| Jerold L. Zimmerman | M | 76 |
Rochester Christian University
| 50 years |
| Bruce L. Crockett | M | 81 |
Rochester Christian University
| - |
| Mark S. Ain | M | 81 |
Rochester Christian University
| - |
| Bobby Sandage | M | 70 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | - |
| Richard Sands | M | 73 |
Rochester Christian University
| - |
| Bala S. Manian | M | 77 |
Rochester Christian University
| - |
| JP Bolduc | M | 84 |
Rochester Christian University
| - |
| Richard T. Aab | M | 75 |
Rochester Christian University
| - |
| William M. Carpenter | M | - |
Rochester Christian University
| - |
| William Balderston | M | 96 |
Rochester Christian University
| - |
| Harold C. Smith | M | - |
Rochester Christian University
| - |
| Arthur Papier | M | - |
Rochester Christian University
| - |
| Benjamin L. Miller | M | - |
Rochester Christian University
| - |
| Todd D. Krauss | M | - |
Rochester Christian University
| - |
| Spencer Z. Rosero | M | - |
Rochester Christian University
| - |
| Ralph R. Whitney | M | 89 |
Rochester Christian University
| - |
| Philip A. Pizzo | M | 79 |
Rochester Christian University
| - |
| Richard A. Kaplan | M | 78 |
Rochester Christian University
| - |
| Duncan Moore | M | - |
Rochester Christian University
| 50 years |
| Lowell A. Goldsmith | M | - |
Rochester Christian University
| - |
| Daniel James Burnside | M | - |
Rochester Christian University
| - |
| Arthur Becker | M | 74 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | 3 years |
| Thomas R. Sloan | M | 79 |
Rochester Christian University
| - |
| Cathy Minehan | F | 77 |
Rochester Christian University
| - |
| William Chin | M | 76 |
Regenacy Pharmaceuticals LLC
Regenacy Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Regenacy Pharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It develops treatments for diabetic and peripheral neuropathies. The firm provides treatments through regeneration of normal protein function using oral, isoform selective histone deacetylase enzyme inhibitors. It provides treatment for diseases such as sickle cell disease, ß-thalassemia, leukemia, and cognitive dysfunction in neurological disorders. The company was founded by Marc A. Cohen in December 2016 and is headquartered in Waltham, MA. | 6 years |
| Ernest Bates | M | - |
Rochester Christian University
| - |
| Fred H. Mermelstein | M | 64 |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | - |
| Thomas Richards | M | 80 |
Rochester Christian University
| - |
| David Klein | M | 75 |
Rochester Christian University
| - |
| Carol Karp | F | 71 |
Rochester Christian University
| - |
| Victor Moyo | M | - |
OncoPep, Inc.
OncoPep, Inc. Investment ManagersFinance OncoPep, Inc. develops immunotherapeutics to prevent the progression of cancer, prolong survival, and restore the quality of life of patients. The company?s product, PVX-410, is a multi-peptide therapeutic cancer vaccine to target specific antigens found on the surface of multiple myeloma cancer cells. Its PVX-410 is targeted for smoldering multiple myeloma, a precursor disease. The company was founded by Doris Peterkin, Joslyn Dobson, and Marc A. Cohen in 2010 and is headquartered in North Andover, MA. | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Walter Ogier | M | 67 |
Acetylon Pharmaceuticals, Inc.
 Acetylon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Acetylon Pharmaceuticals, Inc. develops pharmaceutical technology. It develops novel small molecule drugs which targets epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The company was founded by Ralph Mazitschek, Kenneth C. Anderson, Marc A. Cohen, James E. Bradner, and Walter C. Ogier in October 2008 and is headquartered in Boston, MA. | 8 years |
| Jason S. Fisherman | M | 67 | - | |
| Andrew Phillips | M | 53 | 4 years | |
| Lauren White | F | 45 | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Elena Prokupets
- Personal Network
